When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Liraglutide - Wikipedia

   en.wikipedia.org/wiki/Liraglutide

   Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) receptor agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and ...

3. Weight Loss Injections: What You Need to Know, From ... - AOL

   www.aol.com/lifestyle/weight-loss-injections...

   Liraglutide Weight Loss Injections. Liraglutide is the active ingredient in Saxenda and Victoza. Like Ozempic and Wegovy, liraglutide is an injected GLP-1 receptor agonist that can suppress ...

4. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   Native GLP-1 is a peptide hormone with a half-life of two minutes because it is rapidly cleared by the enzyme dipeptidyl peptidase-4. [29] As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed multiple times per day, daily, weekly, or less often. [29]

5. There’s still no generic Ozempic, but a lower-priced daily ...

   www.aol.com/news/still-no-generic-ozempic-lower...

   The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

6. Teva launches generic version of Novo Nordisk's diabetes drug ...

   www.aol.com/news/teva-launches-generic-version...

   Victoza, chemically known as liraglutide, is a once-daily injection approved for use in adults and children aged 10 or older with type 2 diabetes. ... a first-generation GLP-1, has been on a ...

7. GLP1 poly-agonist peptides - Wikipedia

   en.wikipedia.org/wiki/GLP1_poly-agonist_peptides

   GLP1 poly-agonist peptides [1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor.These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease.